Moreover, the dual PI3K/mTOR inhibitor Gedatolisib has been shown to present greater anti-proliferative activity in PCa cells than single target inhibitors (56), and combination strategies that include PI3K/AKT/mTOR and AR-targeting therapies have shown superior efficacy in androgen-sensitive PCa cell lines and PDX models (57). The gene discussed is AKT1; the disease is posterior cortical atrophy.